Acute kidney injury in patients treated with immune checkpoint inhibitors
-
Published:2021-10
Issue:10
Volume:9
Page:e003467
-
ISSN:2051-1426
-
Container-title:Journal for ImmunoTherapy of Cancer
-
language:en
-
Short-container-title:J Immunother Cancer
Author:
Gupta ShrutiORCID, Short Samuel A P, Sise Meghan E, Prosek Jason M, Madhavan Sethu M, Soler Maria Jose, Ostermann Marlies, Herrmann Sandra M, Abudayyeh Ala, Anand Shuchi, Glezerman Ilya, Motwani Shveta S, Murakami Naoka, Wanchoo Rimda, Ortiz-Melo David I, Rashidi Arash, Sprangers Ben, Aggarwal Vikram, Malik A Bilal, Loew Sebastian, Carlos Christopher A, Chang Wei-Ting, Beckerman Pazit, Mithani Zain, Shah Chintan V, Renaghan Amanda D, Seigneux Sophie De, Campedel Luca, Kitchlu AbhijatORCID, Shin Daniel Sanghoon, Rangarajan Sunil, Deshpande Priya, Coppock Gaia, Eijgelsheim Mark, Seethapathy Harish, Lee Meghan DORCID, Strohbehn Ian A, Owen Dwight H., Husain Marium, Garcia-Carro Clara, Bermejo Sheila, Lumlertgul Nuttha, Seylanova Nina, Flanders Lucy, Isik Busra, Mamlouk OmarORCID, Lin Jamie SORCID, Garcia Pablo, Kaghazchi Aydin, Khanin Yuriy, Kansal Sheru K, Wauters Els, Chandra Sunandana, Schmidt-Ott Kai M, Hsu Raymond K, Tio Maria C, Sarvode Mothi Suraj, Singh Harkarandeep, Schrag Deborah, Jhaveri Kenar D, Reynolds Kerry L, Cortazar Frank B, Leaf David EORCID
Abstract
BackgroundImmune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer.MethodsWe collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI.ResultsICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI.ConclusionsPatients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Cited by
101 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|